Aneesh Vijayan Email & Phone Number

Sassenheim, ZH, NL

Delft, South Holland, Netherlands

• Led a team responsible for preclinical studies and immune assays as the non-clinical lead for the RNA vaccine development program.
• Led several discovery initiatives for novel vaccine platforms within the research organization in the capacity of non-clinical lead.
• Provided strategic support to senior management regarding emerging knowledge in the RNA vaccine space.
• Contributed to due diligence teams exploring new assets of strategic importance for the organization.
• Identified emerging trends in immunology and implemented state-of-the-art immuno-technologies (OMICS, transgenic animal models, etc.) to ensure that research efforts remain at the forefront of innovation.
• Established and maintained strong relationships with key stakeholders across J&J business units and external CROs.

Lille Area, France

• Successfully obtained an EU grant for €185K to conduct research on the mechanism of action (MoA) of mucosal adjuvants.
• Designed and implemented an in vitro lung model to examine the communication between structural cells and immune cells.
• Developed a comprehensive panel for immunophenotyping cells, enabling transcriptomic profiling in the lung compartment of pre-clinical murine models.
• Formed collaborations with academic partners to advance the development of a conjugated protein vaccine.
• Disease targets: Malaria

Paris Area, France

• Formulated a conjugated protein vaccine utilizing click-chemistry against various malaria antigens.
• Implemented procedures for the expression, isolation, refolding, and purification of recombinant antigens from bacteria.
• Developed crucial components of automated downstream processes with large-scale chromatographic units in recombinant protein production.
• Established protocols for generating conjugate vaccines with CRM197 using click chemistry.
• Oversaw collaborations with academic partners and delivered presentations on research findings to key stakeholders.
• Disease targets: Malaria

Community Of Madrid, Spain

• Developed vaccinia based viral vector (MVA) vaccines against malaria and HIV and designed in vivo studies to investigate its immunogenicity in mice and rabbits.
• Designed and generated trimeric gp120 (HIV) protein vaccine from mammalian cells.
• Developed new ligand binding assays to characterize bnAbs against HIV generated by vaccines.
• Developed in vitro cell based assays to study innate immune responses generated by vaccines.
• Established collaborations with US academic partner to generate new transgenic parasites for challenge studies.
• Authored several publications and a patent.

Doctor Of Philosophy (Ph.D.), Immunology

Mres Biomedical Science

Bachelor Of Technology - Btech, Biotechnology